JPMorgan 2023 Deck_FINAL Agios.pdf

1、1Fueled by Connections to Transform Rare DiseasesBrian Goff,Chief Executive OfficerJanuary 11,20232Forward-looking statementsThis presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

2、 1995.Such forward-looking statements include those regarding the potential benefits of PYRUKYND(mitapivat),AG-946 and its PAH stabilizer;Agios plans,strategies and expectations for its preclinical,clinical and commercial advancement of its drug development,including PYRUKYND,AG-946 and its PAH stab

3、ilizer;Agios strategic vision and goals,including its key milestones for 2023 and potential catalysts through 2026;and the potential benefits of Agios strategic plans and focus.The words“anticipate,”“expect,”“goal,”“hope,”“milestone,”“plan,”“potential,”“possible,”“strategy,”“will,”“vision,”and simil

4、ar expressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words.Such statements are subject to numerous important factors,risks and uncertainties that may cause actual events or results to differ materially from Agios cur

5、rent expectations and beliefs.For example,there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases,or that development of any of Agios product candidates will successfully continue.There can

6、be no guarantee that any positive developments in Agios business will result in stock price appreciation.Managements expectations and,therefore,any forward-looking statements in this presentation and various remarks we make during this presentation could also be affected by risks and uncertainties r